Phase 0 5 trials
Phase 0
NCT07647094 Nov 2025 → Oct 2026 expected non-small cell lung carcinoma People's Hospital of Quzhou
Recruiting
No outcome recorded
Phase 0
NCT07034742 Jun 2025 → Jan 2026 overdue gastric adenocarcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Recruiting
No outcome recorded
Phase 0
NCT05238831 Jan 2023 → May 2026 female breast carcinoma , ovarian carcinoma , pancreatic ductal adenocarcinoma , pancreatic large cell neuroendocrine carcinoma +2 OHSU Knight Cancer Institute
Withdrawn
No outcome recorded
Phase 0
NCT04249167 Jan 2020 → Nov 2021 triple-negative breast carcinoma Mayo Clinic
Withdrawn
No outcome recorded
Phase 0
NCT01715142 Mar 2013 → Sep 2015 pancreatic adenocarcinoma Jean-Luc Van Laethem
Completed
No outcome recorded
Phase 1 94 trials · 1 met primary · 2 missed
Phase 1
NCT07488884 Jun 2026 → Jun 2027 expected pancreatic ductal adenocarcinoma ImmunityBio, Inc.
Not yet recruiting
No outcome recorded
Phase 1
NCT07454031 Mar → Dec 2026 expected peritoneum cancer Peking University
Not yet recruiting
No outcome recorded
Phase 1
NCT07253662 Jan 2026 → Dec 2027 expected pancreatic adenocarcinoma Northwell Health
Recruiting
No outcome recorded
Phase 1
NCT07178171 Nov 2025 → Aug 2027 expected triple-negative breast carcinoma Xijing Hospital
Recruiting
No outcome recorded
Phase 1
NCT06675136 Oct 2025 → Jan 2029 expected gastric adenocarcinoma , peritoneum cancer City of Hope Medical Center
Recruiting
No outcome recorded
Phase 1
NCT07377045 Oct 2025 → Mar 2029 expected pancreatic ductal adenocarcinoma Oncomatryx Biopharma S.L.
Recruiting
No outcome recorded
Phase 1
NCT07317609 Jul 2025 → Sep 2027 expected esophageal squamous cell carcinoma Shanghai Zhongshan Hospital
Recruiting
No outcome recorded
Phase 1
NCT06769425 May 2025 → May 2026 overdue female breast carcinoma , gastric cancer , ovarian cancer , prostate cancer +1 Jiangsu Hansoh Pharmaceutical Co., Ltd.
Recruiting
No outcome recorded
Phase 1
NCT06917079 Mar 2025 → Aug 2027 expected colorectal cancer , non-small cell lung carcinoma , pancreatic ductal adenocarcinoma TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Recruiting
No outcome recorded
Phase 1
NCT06076837 Jan → Dec 2025 pancreatic adenocarcinoma HonorHealth Research Institute
Terminated
No outcome recorded
Phase 1
NCT06393400 Jan 2025 → Feb 2028 expected pancreatic ductal adenocarcinoma John Lenehan
Recruiting
No outcome recorded
Phase 1
NCT06704724 Dec 2024 → May 2026 colorectal neoplasm , non-small cell lung carcinoma , pancreatic ductal adenocarcinoma Pfizer
Terminated
No outcome recorded
Stop: Business
Phase 1
NCT06561685 Sep 2024 → Oct 2027 expected metastatic neoplasm , non-small cell lung carcinoma Eli Lilly and Company
Recruiting
No outcome recorded
Phase 1
NCT06611150 Aug 2024 → Aug 2025 overdue nasopharyngeal carcinoma Sun Yat-sen University
Recruiting
No outcome recorded
Phase 1
NCT05653661 Jul 2024 melanoma , metastatic malignant neoplasm Mayo Clinic
Withdrawn
No outcome recorded
Stop: Business
Phase 1
NCT06447662 Jun 2024 → Oct 2026 expected colorectal neoplasm , non-small cell lung carcinoma , pancreatic ductal adenocarcinoma Pfizer
Active not recruiting
No outcome recorded
Phase 1
NCT06182072 Sep 2023 → Jun 2027 expected pancreatic ductal adenocarcinoma ProDa BioTech, LLC
Recruiting
No outcome recorded
Phase 1
NCT05919537 Sep 2023 → Mar 2031 expected malignant pancreatic neoplasm , metastatic neoplasm , non-small cell lung carcinoma Hummingbird Bioscience
Active not recruiting
No outcome recorded
Phase 1
NCT06229496 Aug 2023 → Dec 2027 expected pancreatic adenocarcinoma Chang Gung Memorial Hospital
Recruiting
No outcome recorded
Phase 1
NCT05984602 Jul 2023 → Sep 2025 overdue malignant pancreatic neoplasm NYU Langone Health
Active not recruiting
No outcome recorded
Phase 1
NCT05422794 May 2023 → Mar 2027 expected female breast carcinoma , triple-negative breast carcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT05494866 Dec 2022 → Mar 2024 pancreatic ductal adenocarcinoma German Cancer Research Center
Terminated
No outcome recorded
Phase 1
NCT05497778 Oct 2022 → Feb 2027 expected pancreatic ductal adenocarcinoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT05285358 Sep 2022 → Oct 2028 distal biliary tract carcinoma , gallbladder carcinoma , intrahepatic cholangiocarcinoma , peritoneum cancer City of Hope Medical Center
Suspended
No outcome recorded
Phase 1
NCT05092373 Apr 2022 → Sep 2026 overdue endometrial carcinoma , fallopian tube carcinoma , female breast carcinoma , hepatocellular carcinoma +5 M.D. Anderson Cancer Center
Recruiting
No outcome recorded
Phase 1
NCT05300048 Apr 2022 → Apr 2025 neoplasm Faeth Therapeutics
Terminated
No outcome recorded
Phase 1
NCT05251766 Apr → Dec 2022 breast cancer , chemotherapy-induced toxicity Xuli Meng
Unknown
No outcome recorded
Phase 1
NCT05267470 Mar 2022 → May 2024 non-small cell squamous lung carcinoma Amgen
Terminated
No outcome recorded
Stop: Business
Phase 1
NCT05075993 Nov 2021 → Feb 2027 expected esophageal cancer , gastric cancer , head and neck carcinoma , hepatocellular carcinoma +4 M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT04158635 Sep 2021 → Mar 2027 malignant pancreatic neoplasm City of Hope Medical Center
Suspended
No outcome recorded
Stop: Enrollment
Phase 1
NCT04787991 Aug 2021 → Nov 2024 pancreatic adenocarcinoma Cancer Insight, LLC
Completed
No outcome recorded
Phase 1
NCT05390710 Jun 2021 → Dec 2023 triple-negative breast carcinoma Laekna Limited
Completed
No outcome recorded
Phase 1
NCT04634539 May 2021 → Jul 2023 pancreatic ductal adenocarcinoma Jun Gong, MD
Completed
No outcome recorded
Phase 1
NCT04850235 Apr 2021 → Dec 2022 nasopharyngeal carcinoma Sun Yat-sen University
Unknown
No outcome recorded
Phase 1
NCT06538207 Jan 2021 → Oct 2024 malignant pancreatic neoplasm Ono Pharmaceutical Co., Ltd.
Completed
No outcome recorded
Phase 1
NCT04000906 Nov 2020 → Dec 2023 peritoneal carcinomatosis University Hospital, Geneva
Unknown
No outcome recorded
Phase 1
NCT04584112 Sep 2020 → Mar 2023 triple-negative breast carcinoma Hoffmann-La Roche
Completed
No outcome recorded
Phase 1
NCT04132817 Sep 2020 → Aug 2022 breast cancer Bristol-Myers Squibb
Completed
No outcome recorded
Phase 1
NCT03878524 Apr → Dec 2020 acute myeloid leukemia , atypical chronic myeloid leukemia, BCR-ABL1 negative , blast phase chronic myelogenous leukemia, BCR-ABL1 positive , castration-resistant prostate carcinoma +14 OHSU Knight Cancer Institute
Terminated
No outcome recorded
Stop: Enrollment
Phase 1
NCT04306900 Mar 2020 → Nov 2022 cancer Trishula Therapeutics, Inc.
Completed
No outcome recorded
Phase 1
NCT03554044 Feb 2020 → Dec 2023 Her2-receptor negative breast cancer , estrogen-receptor positive breast cancer , female breast carcinoma , invasive breast carcinoma University of California, San Francisco
Completed
No outcome recorded
Phase 1
NCT04196283 Jan 2020 → Oct 2022 cancer of unknown primary site AbbVie
Completed
No outcome recorded
Phase 1
NCT03977220 Jan 2020 → Dec 2021 gastric cancer Shanghai Zhongshan Hospital
Unknown
No outcome recorded
Phase 1
NCT04046887 Sep 2019 → May 2021 pancreatic ductal adenocarcinoma Patrick Joseph Loehrer Sr.
Terminated
No outcome recorded
Phase 1
NCT03893955 May 2019 → Mar 2026 overdue metastatic neoplasm , non-small cell lung carcinoma , triple-negative breast carcinoma AbbVie
Active not recruiting
No outcome recorded
Phase 1
NCT03003546 Apr 2019 → May 2023 aggressive B-cell non-Hodgkin lymphoma , chronic lymphocytic leukemia/small lymphocytic lymphoma Mayo Clinic
Completed
No outcome recorded
Phase 1
NCT03703063 Sep 2018 → Sep 2021 pancreatic ductal adenocarcinoma Benaroya Research Institute
Unknown
No outcome recorded
Phase 1
NCT03507491 Aug 2018 → Feb 2024 cancer Emory University
Completed
No outcome recorded
Phase 1
NCT03703089 May 2018 → May 2022 pancreatic adenocarcinoma Benaroya Research Institute
Unknown
No outcome recorded
Phase 1
NCT03421353 Feb 2018 → Jan 2020 cancer AstraZeneca
Completed
No outcome recorded
Phase 1
NCT03307785 Oct 2017 → Feb 2020 metastatic malignant neoplasm , non-small cell lung carcinoma Tesaro, Inc.
Completed
No outcome recorded
Phase 1
NCT03166085 May 2017 → Dec 2021 breast cancer Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 1
NCT02999477 Feb 2017 → Nov 2022 breast cancer Adrienne G. Waks
Completed
Missed primary
Phase 1
NCT02930902 Feb 2017 → Jan 2023 digestive system carcinoma , malignant exocrine pancreas neoplasm M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT02857270 Sep 2016 → Feb 2021 colorectal cancer , metastatic melanoma , non-small cell lung carcinoma Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT02798536 Jul 2016 → Jul 2017 mesothelioma National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1
NCT02608229 Jun 2016 → Mar 2019 malignant pancreatic neoplasm Washington University School of Medicine
Terminated
No outcome recorded
Phase 1
NCT02658214 Apr 2016 → Nov 2019 esophageal squamous cell carcinoma , fallopian tube neoplasm , gastric neoplasm , gastroesophageal cancer +6 AstraZeneca
Completed
No outcome recorded
Phase 1
NCT02715531 Apr 2016 → May 2021 cancer Hoffmann-La Roche
Completed
No outcome recorded
Phase 1
NCT02622074 Jan 2016 → May 2018 triple-negative breast carcinoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT02620800 Jan 2016 → Oct 2018 pancreatic adenocarcinoma Celgene Corporation
Completed
No outcome recorded
Phase 1
NCT03307148 Jan 2016 → Mar 2019 pancreatic adenocarcinoma Barts & The London NHS Trust
Completed
No outcome recorded
Phase 1
NCT02300935 Dec 2015 → Jan 2016 melanoma SCRI Development Innovations, LLC
Withdrawn
No outcome recorded
Phase 1
NCT02501902 Nov 2015 → Oct 2018 pancreatic ductal adenocarcinoma Pfizer
Completed
Missed primary
Phase 1
NCT02394535 Nov 2015 → Aug 2022 pancreatic adenocarcinoma M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT02588443 Oct 2015 → Nov 2018 malignant pancreatic neoplasm Abramson Cancer Center at Penn Medicine
Completed
No outcome recorded
Phase 1
NCT02574663 Sep 2015 → Aug 2018 esophageal cancer , gastric cancer , gastrointestinal stromal tumor , pancreatic adenocarcinoma +1 TG Therapeutics, Inc.
Completed
No outcome recorded
Phase 1
NCT02506803 Jul 2015 → Jun 2017 malignant pancreatic neoplasm Wakayama Medical University
Unknown
No outcome recorded
Phase 1
NCT02514421 Jul 2015 → Apr 2017 pancreatic adenocarcinoma The University of Texas Health Science Center, Houston
Completed
No outcome recorded
Phase 1
NCT02267707 May 2015 → Feb 2016 cholestasis , malignant pancreatic neoplasm Celgene Corporation
Terminated
No outcome recorded
Phase 1
NCT02117817 Feb 2015 endometrial cancer , ovarian cancer Rutgers, The State University of New Jersey
Withdrawn
No outcome recorded
Phase 1
NCT02283372 Jan 2015 → May 2018 malignant exocrine pancreas neoplasm Washington University School of Medicine
Completed
No outcome recorded
Phase 1
NCT02309177 Jan 2015 → Sep 2018 breast neoplasm , pancreatic neoplasm Celgene Corporation
Completed
No outcome recorded
Phase 1
NCT02707328 Jan 2015 → Nov 2017 pancreatic adenocarcinoma The Cooper Health System
Terminated
No outcome recorded
Phase 1
NCT02317419 Dec 2014 → Aug 2015 cancer Hoffmann-La Roche
Terminated
No outcome recorded
Phase 1
NCT02155088 Oct 2014 → Dec 2016 malignant pancreatic neoplasm H. Lee Moffitt Cancer Center and Research Institute
Completed
No outcome recorded
Phase 1
NCT02174887 Sep 2014 → Oct 2016 pancreatic adenocarcinoma Institut Paoli-Calmettes
Completed
No outcome recorded
Phase 1
NCT02138383 May 2014 → Dec 2016 malignant pancreatic neoplasm H. Lee Moffitt Cancer Center and Research Institute
Completed
No outcome recorded
Phase 1
NCT02020707 Feb 2014 → Jul 2024 carcinosarcoma of the corpus uteri , cervical adenosarcoma , cervical adenosquamous carcinoma , cervical carcinosarcoma +23 Mayo Clinic
Completed
No outcome recorded
Phase 1
NCT02047500 Jan 2014 → Sep 2015 pancreatic adenocarcinoma ImmunoGenesis
Terminated
No outcome recorded
Phase 1
NCT02272738 Aug 2013 → Nov 2015 pancreatic adenocarcinoma Osaka Medical Center for Cancer and Cardiovascular Diseases
Completed
No outcome recorded
Phase 1
NCT01840579 Apr 2013 → Feb 2020 non-small cell lung carcinoma , small cell lung carcinoma Merck Sharp & Dohme LLC
Completed
No outcome recorded
Phase 1
NCT01822756 Apr 2013 → Sep 2015 malignant pancreatic neoplasm Incyte Corporation
Terminated
No outcome recorded
Phase 1
NCT01633970 Jul 2012 → Feb 2020 cancer Genentech, Inc.
Completed
No outcome recorded
Phase 1
NCT01192165 Sep 2010 → Oct 2013 cancer GlaxoSmithKline
Completed
Met primary
Phase 1
NCT01161186 Jul 2010 → Oct 2012 pancreatic adenocarcinoma University of California, San Francisco
Completed
No outcome recorded
Phase 1
NCT01113476 Apr 2010 → Aug 2022 —
M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT01010945 Feb 2010 → Jan 2012 pancreatic neoplasm OSI Pharmaceuticals
Completed
No outcome recorded
Phase 1
NCT00983424 Feb 2010 → May 2013 breast cancer Northwestern University
Completed
No outcome recorded
Phase 1
NCT01057264 Jan 2010 → May 2014 high grade malignant neoplasm M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT00970996 Sep 2009 → Dec 2012 melanoma M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT00833807 Feb 2009 → Nov 2014 metastatic melanoma M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT00825201 Jan 2009 → Jan 2018 cancer of unknown primary site , ovarian cancer , peritoneum cancer City of Hope Medical Center
Completed
No outcome recorded
Phase 1
NCT00732836 Jun 2008 → Jan 2016 liver cancer M.D. Anderson Cancer Center
Completed
No outcome recorded
Show 84 more trials Phase 1/2 82 trials · 4 met primary · 5 missed
Phase 1/2
NCT07475234 Mar 2026 → Dec 2028 expected pancreatic ductal adenocarcinoma Xiuchao Wang
Not yet recruiting
No outcome recorded
Phase 1/2
NCT07361991 Mar 2026 → Sep 2028 expected —
The First Affiliated Hospital of Zhengzhou University
Not yet recruiting
No outcome recorded
Phase 1/2
NCT07223047 Nov 2025 → Oct 2028 expected colorectal cancer , high grade malignant neoplasm , non-small cell lung carcinoma , pancreatic ductal adenocarcinoma Bristol-Myers Squibb
Recruiting
No outcome recorded
Phase 1/2
NCT07140393 Oct 2025 → Oct 2027 expected neoplasm Jiangsu HengRui Medicine Co., Ltd.
Recruiting
No outcome recorded
Phase 1/2
NCT07312422 Sep 2025 → Apr 2026 overdue malignant pancreatic neoplasm Zhejiang Provincial People's Hospital
Recruiting
No outcome recorded
Phase 1/2
NCT06483555 Feb 2025 → Aug 2027 expected basal cell neoplasm , pancreatic adenocarcinoma UNC Lineberger Comprehensive Cancer Center
Recruiting
No outcome recorded
Phase 1/2
NCT06513455 Sep 2024 → Jun 2027 expected malignant pancreatic neoplasm Harbin Medical University
Not yet recruiting
No outcome recorded
Phase 1/2
NCT06140576 Nov 2023 → Dec 2025 overdue breast neoplasm Zhejiang Cancer Hospital
Not yet recruiting
No outcome recorded
Phase 1/2
NCT05832892 Nov 2023 → Nov 2024 neoplastic disease or syndrome Shanghai Zhongshan Hospital
Unknown
No outcome recorded
Phase 1/2
NCT05501665 May 2023 → Feb 2026 overdue non-small cell lung carcinoma Vanderbilt-Ingram Cancer Center
Recruiting
No outcome recorded
Phase 1/2
NCT05794477 Apr 2023 → Jul 2025 neoplasm Shanghai Hengrui Pharmaceutical Co., Ltd.
Unknown
No outcome recorded
Phase 1/2
NCT05669482 Mar 2023 → Aug 2026 overdue malignant pancreatic neoplasm , metastatic malignant neoplasm Verastem, Inc.
Active not recruiting
No outcome recorded
Phase 1/2
NCT06173986 Jan 2023 → Dec 2025 overdue esophageal squamous cell carcinoma Shanghai Chest Hospital
Recruiting
No outcome recorded
Phase 1/2
NCT05918133 Jul 2022 → Oct 2026 expected triple-negative breast carcinoma BioNTech SE
Active not recruiting
No outcome recorded
Phase 1/2
NCT05383482 Jul 2022 → Jun 2024 cervical cancer , endometrial cancer , esophageal cancer , gastroesophageal adenocarcinoma +1 Laekna Limited
Completed
No outcome recorded
Phase 1/2
NCT05253053 Apr 2022 → Aug 2024 cholangiocarcinoma , gallbladder cancer , gastric cancer , prostate cancer +4 TransThera Sciences (Nanjing), Inc.
Completed
No outcome recorded
Phase 1/2
NCT05327582 Apr 2022 → Apr 2023 biliary tract cancer , malignant pancreatic neoplasm Chinese PLA General Hospital
Unknown
No outcome recorded
Phase 1/2
NCT05257993 Mar 2022 → Apr 2030 expected pancreatic ductal adenocarcinoma Onconic Therapeutics Inc.
Recruiting
No outcome recorded
Phase 1/2
NCT05218889 Aug 2021 → Dec 2024 overdue pancreatic ductal adenocarcinoma Chinese PLA General Hospital
Recruiting
No outcome recorded
Phase 1/2
NCT04742959 Mar 2021 → Feb 2024 cholangiocarcinoma , gallbladder cancer , gastric cancer , prostate cancer +5 TransThera Sciences (Nanjing), Inc.
Completed
No outcome recorded
Phase 1/2
NCT04572542 Jan 2020 → Jun 2021 gastroesophageal adenocarcinoma The First Affiliated Hospital of Xiamen University
Unknown
No outcome recorded
Phase 1/2
NCT04324307 Nov 2019 → Nov 2023 —
Changhai Hospital
Unknown
No outcome recorded
Phase 1/2
NCT04182724 Nov 2019 → May 2021 gastric cancer Chinese PLA General Hospital
Unknown
No outcome recorded
Phase 1/2
NCT04143711 Nov 2019 → Dec 2025 cancer Dragonfly Therapeutics
Completed
No outcome recorded
Phase 1/2
NCT04152057 Nov 2019 → Apr 2020 HER2 positive breast carcinoma West China Hospital
Unknown
No outcome recorded
Phase 1/2
NCT04148885 Nov 2019 → Jul 2020 castration-resistant prostate carcinoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Unknown
No outcome recorded
Phase 1/2
NCT03872791 May 2019 → Aug 2022 triple-negative breast carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Completed
Met primary
Phase 1/2
NCT03652428 Apr 2019 → Dec 2026 expected pancreatic neoplasm University of Maryland, Baltimore
Recruiting
No outcome recorded
Phase 1/2
NCT03840915 Apr 2019 → Jul 2022 non-small cell lung carcinoma EMD Serono Research & Development Institute, Inc.
Completed
No outcome recorded
Phase 1/2
NCT04004234 Mar 2019 → Aug 2020 biliary tract cancer Chinese PLA General Hospital
Unknown
No outcome recorded
Phase 1/2
NCT03649321 Jan 2019 → Jun 2022 pancreatic adenocarcinoma University of Texas Southwestern Medical Center
Terminated
No outcome recorded
Stop: Business
Phase 1/2
NCT03524898 Oct 2018 → Feb 2022 soft tissue sarcoma Swiss Cancer Institute
Terminated
No outcome recorded
Phase 1/2
NCT03563157 Sep 2018 → Apr 2019 colorectal cancer ImmunityBio, Inc.
Terminated
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT03169777 Aug 2018 → Jan 2019 colorectal cancer ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03633734 Jul 2018 → Aug 2023 chemotherapy-induced toxicity , pancreatic adenocarcinoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Unknown
No outcome recorded
Phase 1/2
NCT03535727 Jun 2018 → Oct 2022 adenocarcinoma , endocrine gland neoplasm , pancreatic neoplasm Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed
No outcome recorded
Phase 1/2
NCT03611556 Jun 2018 → Jul 2022 pancreatic adenocarcinoma MedImmune LLC
Completed
Missed primary
Phase 1/2
NCT03563170 May 2018 → Aug 2019 hepatocellular carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT03424005 Mar 2018 → Sep 2030 expected breast cancer Hoffmann-La Roche
Recruiting
No outcome recorded
Phase 1/2
NCT03169738 Feb 2018 → Jan 2019 non-small cell lung carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03387111 Jan 2018 → Apr 2019 squamous cell carcinoma ImmunityBio, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT03387098 Dec 2017 → Sep 2018 malignant pancreatic neoplasm ImmunityBio, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT03167164 Dec 2017 → Jan 2019 cutaneous neuroendocrine carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03169790 Dec 2017 → Jan 2019 non-Hodgkin lymphoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03175666 Dec 2017 → Jan 2019 triple-negative breast carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03197571 Dec 2017 → Jan 2019 urothelial carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03169764 Dec 2017 → Jan 2019 head and neck squamous cell carcinoma ImmunityBio, Inc.
Withdrawn
No outcome recorded
Phase 1/2
NCT03329248 Nov 2017 → Aug 2018 malignant pancreatic neoplasm ImmunityBio, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT03136406 Aug → Nov 2017 malignant pancreatic neoplasm ImmunityBio, Inc.
Terminated
No outcome recorded
Phase 1/2
NCT03184870 Aug 2017 → Apr 2023 colorectal cancer , malignant pancreatic neoplasm Bristol-Myers Squibb
Completed
No outcome recorded
Phase 1/2
NCT03943043 Jul 2017 → Sep 2020 cholangiocarcinoma Istituto Clinico Humanitas
Unknown
Missed primary
Phase 1/2
NCT03193190 Jul 2017 → Feb 2025 pancreatic adenocarcinoma Hoffmann-La Roche
Completed
Missed primary
Phase 1/2
NCT03085914 May 2017 → Jan 2019 cancer Incyte Corporation
Completed
No outcome recorded
Phase 1/2
NCT02733250 Mar 2017 → Apr 2019 lung cancer University of Montreal Hospital Centre (CHUM)
Completed
No outcome recorded
Phase 1/2
NCT02481635 Dec 2016 → May 2024 malignant pancreatic neoplasm University Health Network, Toronto
Completed
No outcome recorded
Phase 1/2
NCT02810418 Aug 2016 → Jan 2019 pancreatic neoplasm National Cancer Institute (NCI)
Completed
No outcome recorded
Phase 1/2
NCT02762981 May 2016 → May 2020 cancer Corcept Therapeutics
Completed
No outcome recorded
Phase 1/2
NCT02759588 May 2016 → Dec 2021 fallopian tube cancer , ovarian cancer , peritoneal carcinomatosis Genelux GmbH
Completed
Met primary
Phase 1/2
NCT02024009 Mar 2016 → Jun 2021 pancreatic neoplasm University of Oxford
Completed
No outcome recorded
Phase 1/2
NCT02358161 Sep 2015 → Sep 2018 malignant pancreatic neoplasm Academic Medical Center - University of Amsterdam
Completed
No outcome recorded
Phase 1/2
NCT02504333 Jul 2015 → Apr 2021 pancreatic adenocarcinoma Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Completed
Met primary
Phase 1/2
NCT02382406 Jun 2015 → Apr 2022 non-small cell lung carcinoma Nisha Mohindra, MD
Terminated
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT02379247 Feb 2015 → Sep 2017 breast cancer Priyanka Sharma
Completed
No outcome recorded
Phase 1/2
NCT02331251 Dec 2014 → Jan 2018 breast cancer , cancer of unknown primary site , ovarian carcinoma , pancreatic adenocarcinoma +2 Western Regional Medical Center
Terminated
Missed primary
Phase 1/2
NCT02178436 Oct 2014 → Nov 2021 pancreatic acinar cell carcinoma , pancreatic ductal adenocarcinoma Mohammed Najeeb Al Hallak
Completed
No outcome recorded
Phase 1/2
NCT02273713 Oct 2014 → Mar 2017 esophageal cancer , poisoning Academic Medical Center - University of Amsterdam
Completed
No outcome recorded
Phase 1/2
NCT02065466 Jul 2014 → Feb 2015 metastatic malignant neoplasm in the brain , metastatic melanoma University of Arizona
Withdrawn
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT02762474 Jul 2014 → Nov 2017 esophageal cancer Tianjin Medical University Cancer Institute and Hospital
Unknown
No outcome recorded
Phase 1/2
NCT02075021 Mar 2014 → Nov 2015 refractory plasma cell neoplasm NYU Langone Health
Terminated
No outcome recorded
Phase 1/2
NCT01962103 Dec 2013 → Dec 2017 Ewing sarcoma , dermatofibrosarcoma protuberans , epithelioid sarcoma , histiocytoma +5 Celgene Corporation
Completed
No outcome recorded
Phase 1/2
NCT01971281 Nov 2013 → Dec 2017 pancreatic adenocarcinoma NovoCure Ltd.
Unknown
No outcome recorded
Phase 1/2
NCT01858883 Jun 2013 → Feb 2016 malignant pancreatic neoplasm Incyte Corporation
Completed
No outcome recorded
Phase 1/2
NCT01893801 May 2013 → Apr 2016 pancreas disorder Pancreatic Cancer Research Team
Completed
Missed primary
Phase 1/2
NCT02382263 Apr 2013 → Apr 2016 pancreatic neoplasm PH Research, S.L.
Completed
No outcome recorded
Phase 1/2
NCT01757288 Mar 2013 → Jun 2019 non-small cell lung carcinoma University of Texas Southwestern Medical Center
Completed
No outcome recorded
Phase 1/2
NCT01632306 Mar 2013 → Jun 2015 malignant pancreatic neoplasm Eli Lilly and Company
Terminated
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT01730222 Nov 2012 → Feb 2017 pancreatic adenocarcinoma IRCCS San Raffaele
Completed
Met primary
Phase 1/2
NCT01488552 Nov 2011 → Aug 2015 pancreas disorder Pancreatic Cancer Research Team
Completed
No outcome recorded
Phase 1/2
NCT00851877 Mar 2009 → Oct 2013 head and neck cancer University of Texas Southwestern Medical Center
Completed
No outcome recorded
Phase 1/2
NCT00748553 Sep 2008 → Oct 2015 breast cancer University of Utah
Completed
No outcome recorded
Phase 1/2
NCT00544648 Nov 2007 → Apr 2014 lung cancer Vanderbilt-Ingram Cancer Center
Terminated
No outcome recorded
Stop: Enrollment
Phase 1/2
NCT00470548 Apr 2007 → Oct 2014 breast cancer , lung cancer University of California, Davis
Terminated
No outcome recorded
Show 72 more trials Phase 2 372 trials · 12 met primary · 12 missed
Phase 2
NCT07258147 Oct 2026 → Dec 2027 expected small cell lung carcinoma Sichuan University
Not yet recruiting
No outcome recorded
Phase 2
NCT07628062 Jul 2026 → Dec 2030 expected oropharynx squamous cell carcinoma ImmunityBio, Inc.
Not yet recruiting
No outcome recorded
Phase 2
NCT07492680 Jul 2026 → Aug 2028 expected cancer Bristol-Myers Squibb
Not yet recruiting
No outcome recorded
Phase 2
NCT07683221 Jul 2026 → Jul 2029 expected malignant pancreatic neoplasm Shandong Cancer Hospital and Institute
Not yet recruiting
No outcome recorded
Phase 2
NCT07711470 Jul 2026 → Dec 2028 expected esophageal squamous cell carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Active not recruiting
No outcome recorded
Phase 2
NCT07493993 Jun 2026 → May 2028 expected esophageal squamous cell carcinoma Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07616362 Jun 2026 → Apr 2029 expected pancreatic ductal adenocarcinoma Federation Francophone de Cancerologie Digestive
Not yet recruiting
No outcome recorded
Phase 2
NCT07618910 May 2026 → May 2027 expected esophageal squamous cell carcinoma Tang-Du Hospital
Not yet recruiting
No outcome recorded
Phase 2
NCT07595770 May 2026 → Jan 2028 expected esophageal squamous cell carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
No outcome recorded
Phase 2
NCT07610629 May 2026 → Dec 2028 expected gastric adenocarcinoma Henan Cancer Hospital
Not yet recruiting
No outcome recorded
Show all 372 trials opens the full record — a long page Phase 2/3 12 trials · 1 met primary
Phase 2/3
NCT07463313 Mar 2026 → Mar 2029 expected combined thymoma Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not yet recruiting
No outcome recorded
Phase 2/3
NCT07044453 Dec 2025 → Sep 2030 expected pancreatic adenocarcinoma University Hospital, Rouen
Recruiting
No outcome recorded
Phase 2/3
NCT06115499 Aug 2024 → Jan 2029 expected pancreatic acinar cell carcinoma , pancreatic adenosquamous carcinoma , pancreatic ductal adenocarcinoma Alliance for Clinical Trials in Oncology
Active not recruiting
No outcome recorded
Phase 2/3
NCT06361888 May 2024 → May 2028 expected malignant pancreatic neoplasm Hutchmed
Recruiting
No outcome recorded
Phase 2/3
NCT06288373 Apr 2024 → Mar 2031 expected cervical cancer Tongji Hospital
Recruiting
No outcome recorded
Phase 2/3
NCT06907602 Jan 2024 → Dec 2026 expected esophageal squamous cell carcinoma Peking Union Medical College Hospital
Recruiting
No outcome recorded
Phase 2/3
NCT06037980 Nov 2023 → Dec 2028 expected cholangiocarcinoma Gruppo Oncologico del Nord-Ovest
Recruiting
No outcome recorded
Phase 2/3
NCT05555706 Dec 2022 → Sep 2024 triple-negative breast carcinoma Shanghai Jiaolian Drug Research and Development Co., Ltd
Completed
No outcome recorded
Phase 2/3
NCT04435652 Jul 2020 → Apr 2022 gastroesophageal adenocarcinoma Qilu Pharmaceutical Co., Ltd.
Unknown
No outcome recorded
Phase 2/3
NCT06341998 Jun 2020 → Jan 2024 yolk sac tumor Shandong First Medical University
Completed
No outcome recorded
Phase 2/3
NCT01881230 Sep 2013 → Oct 2016 triple-negative breast carcinoma Celgene Corporation
Completed
Met primary
Phase 2/3
NCT01204437 Mar 2009 → Jan 2014 breast cancer GBG Forschungs GmbH
Completed
No outcome recorded
Show 2 more trials Phase 3 44 trials · 8 met primary · 5 missed
Phase 3
NCT07715396 Oct 2026 → Oct 2031 expected non-small cell lung carcinoma AIO-Studien-gGmbH
Not yet recruiting
No outcome recorded
Phase 3
NCT07562152 Jun 2026 → Jun 2028 expected pancreatic ductal adenocarcinoma Immuneering Corporation
Recruiting
No outcome recorded
Phase 3
NCT07491445 Mar 2026 → Jun 2028 expected pancreatic adenosquamous carcinoma , pancreatic ductal adenocarcinoma Revolution Medicines, Inc.
Recruiting
No outcome recorded
Phase 3
NCT06952621 Feb 2026 → Dec 2027 expected esophageal squamous cell carcinoma Tang-Du Hospital
Not yet recruiting
No outcome recorded
Phase 3
NCT07371611 Jan 2026 → Dec 2030 expected oral cavity squamous cell carcinoma Qunxing Li,MD
Recruiting
No outcome recorded
Phase 3
NCT07235930 Nov 2025 → Jul 2029 expected exocrine pancreatic carcinoma Zhejiang Cancer Hospital
Recruiting
No outcome recorded
Phase 3
NCT07155629 Sep 2025 → Aug 2030 expected pancreas disorder Helsinki University Central Hospital
Not yet recruiting
No outcome recorded
Phase 3
NCT07057427 Jun 2025 → Jun 2028 expected breast cancer Henan Cancer Hospital
Recruiting
No outcome recorded
Phase 3
NCT06897644 Mar 2025 → Jan 2029 expected pancreatic adenocarcinoma Gruppo Oncologico del Nord-Ovest
Recruiting
No outcome recorded
Phase 3
NCT06096844 Jul 2024 → Jan 2035 expected non-small cell lung carcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 3
NCT06438627 May 2024 → May 2026 overdue nasopharyngeal carcinoma XIANG YANQUN
Recruiting
No outcome recorded
Phase 3
NCT06383780 May 2024 → May 2027 expected nasopharyngeal carcinoma XIANG YANQUN
Recruiting
No outcome recorded
Phase 3
NCT06714604 Oct 2023 → Dec 2032 expected pancreatic adenocarcinoma Sahlgrenska University Hospital
Recruiting
No outcome recorded
Phase 3
NCT05954442 Sep 2023 → Aug 2025 overdue triple-negative breast carcinoma Fudan University
Recruiting
No outcome recorded
Phase 3
NCT05919030 Jul 2023 → Jul 2026 overdue esophageal squamous cell carcinoma Renmin Hospital of Wuhan University
Recruiting
No outcome recorded
Phase 3
NCT05493501 Dec 2022 → Aug 2023 non-small cell lung carcinoma EQRx International, Inc.
Terminated
No outcome recorded
Phase 3
NCT05582265 Oct 2022 → Oct 2028 expected head and neck squamous cell carcinoma Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting
No outcome recorded
Phase 3
NCT05257408 Jun 2022 → Mar 2025 overdue fallopian tube neoplasm , ovarian neoplasm , peritoneal neoplasm Corcept Therapeutics
Active not recruiting
Met primary
Phase 3
NCT04137653 Jul 2021 → Nov 2025 overdue breast cancer Shengjing Hospital
Recruiting
No outcome recorded
Phase 3
NCT05429684 Jan 2021 → Feb 2024 HER2 positive breast carcinoma First Affiliated Hospital Xi'an Jiaotong University
Unknown
No outcome recorded
Phase 3
NCT04793932 Nov 2020 → Mar 2025 overdue pancreatic ductal adenocarcinoma Associazione Italiana per lo Studio del Pancreas
Active not recruiting
Met primary
Phase 3
NCT04547907 Sep 2020 → Dec 2024 overdue HER2 positive breast carcinoma Henan Cancer Hospital
Recruiting
Met primary
Phase 3
NCT04335006 Jul 2020 → Apr 2023 triple-negative breast carcinoma Jiangsu HengRui Medicine Co., Ltd.
Terminated
No outcome recorded
Stop: Business
Phase 3
NCT04135781 Mar 2020 → Oct 2024 gastric cancer Zhejiang Cancer Hospital
Unknown
No outcome recorded
Phase 3
NCT04148911 Dec 2019 → Dec 2024 triple-negative breast carcinoma Hoffmann-La Roche
Completed
No outcome recorded
Phase 3
NCT03768414 Feb 2019 → Oct 2023 distal biliary tract carcinoma , gallbladder carcinoma , intrahepatic cholangiocarcinoma SWOG Cancer Research Network
Completed
Missed primary
Phase 3
NCT03750669 Oct 2018 → Nov 2024 pancreatic adenocarcinoma Second Affiliated Hospital, School of Medicine, Zhejiang University
Completed
No outcome recorded
Phase 3
NCT03594747 Jul 2018 → Sep 2020 non-small cell lung carcinoma BeiGene
Completed
Met primary
Phase 3
NCT03262948 Dec 2017 → Oct 2019 non-small cell lung carcinoma CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Unknown
No outcome recorded
Phase 3
NCT02715804 Mar 2016 → Nov 2019 pancreatic ductal adenocarcinoma Halozyme Therapeutics
Terminated
Missed primary
Stop: Business
Phase 3
NCT02546934 Mar 2016 → Apr 2020 breast cancer Fudan University
Completed
Met primary
Phase 3
NCT02344472 Sep 2015 → Jan 2025 breast cancer University of Ulm
Unknown
No outcome recorded
Phase 3
NCT02367794 Jun 2015 → Oct 2018 non-small cell squamous lung carcinoma Hoffmann-La Roche
Completed
Mixed
Phase 3
NCT02506842 Jun 2015 → Dec 2018 pancreatic neoplasm Fudan University
Unknown
No outcome recorded
Phase 3
NCT02367781 Apr 2015 → Mar 2018 non-small cell lung carcinoma Hoffmann-La Roche
Completed
Met primary
Phase 3
NCT01964430 Mar 2014 → Jun 2022 endocrine gland neoplasm , pancreatic neoplasm Celgene Corporation
Completed
Missed primary
Phase 3
NCT02019277 Dec 2013 → Nov 2016 female breast carcinoma Hoffmann-La Roche
Completed
No outcome recorded
Phase 3
NCT01836432 May 2013 → Jul 2016 pancreatic ductal adenocarcinoma NewLink Genetics Corporation
Terminated
Missed primary
Phase 3
NCT01690702 Sep 2012 → Sep 2018 breast cancer GBG Forschungs GmbH
Completed
No outcome recorded
Phase 3
NCT01583426 Jul 2012 → Dec 2018 HER2 positive breast carcinoma , breast mucinous carcinoma , female breast carcinoma , inflammatory breast carcinoma +1 GBG Forschungs GmbH
Completed
Met primary
Phase 3
NCT01572038 Jun 2012 → Sep 2019 breast neoplasm Hoffmann-La Roche
Completed
No outcome recorded
Phase 3
NCT00844649 Mar 2009 → Sep 2012 malignant pancreatic neoplasm Celgene Corporation
Completed
Met primary
Phase 3
NCT00785291 Oct 2008 → Dec 2013 HER2 positive breast carcinoma , Her2-receptor negative breast cancer , estrogen-receptor negative breast cancer , estrogen-receptor positive breast cancer +2 National Cancer Institute (NCI)
Completed
Missed primary
Phase 3
NCT00540514 Nov 2007 → Oct 2009 non-small cell lung carcinoma Celgene Corporation
Completed
No outcome recorded
Show 34 more trials Phase 4 12 trials · 1 met primary
Phase 4
NCT06357598 Jan → Dec 2024 non-small cell lung carcinoma The Affiliated Hospital of Qingdao University
Unknown
No outcome recorded
Phase 4
NCT05689671 Dec 2023 → Mar 2026 overdue non-small cell lung carcinoma Nikolaj Frost MD
Active not recruiting
No outcome recorded
Phase 4
NCT05843292 Jul 2023 → Dec 2024 overdue triple-negative breast carcinoma Shanghai Jiao Tong University School of Medicine
Not yet recruiting
No outcome recorded
Phase 4
NCT05420467 Jul 2022 → Jul 2027 expected breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 4
NCT05420454 Jul 2022 → Jun 2027 expected breast cancer Second Affiliated Hospital, School of Medicine, Zhejiang University
Recruiting
No outcome recorded
Phase 4
NCT04554524 Aug 2020 → Jul 2024 combined thymoma Tang-Du Hospital
Unknown
No outcome recorded
Phase 4
NCT04480268 Jul 2020 → Jan 2022 pancreatic ductal adenocarcinoma IRCCS San Raffaele
Unknown
No outcome recorded
Phase 4
NCT04182568 Aug 2019 → Aug 2021 breast cancer Xijing Hospital
Unknown
No outcome recorded
Phase 4
NCT04031885 Aug 2019 → Aug 2020 breast cancer Eli Lilly and Company
Terminated
No outcome recorded
Stop: Enrollment
Phase 4
NCT03799679 Nov 2018 → Nov 2019 triple-negative breast carcinoma Fudan University
Unknown
No outcome recorded
Phase 4
NCT03401827 Mar 2018 → Jan 2019 chemotherapy-induced toxicity , pancreatic ductal adenocarcinoma Seoul National University Hospital
Unknown
Met primary
Phase 4
NCT02151149 Jun 2014 → Jul 2017 adenocarcinoma , large cell carcinoma , non-small cell lung carcinoma , squamous cell carcinoma Celgene Corporation
Completed
No outcome recorded
Show 2 more trials Phase not applicable 12 trials
— NCT07538193 May 2026 → May 2029 expected metastatic malignant neoplasm in the lymph nodes , non-small cell lung carcinoma Tang-Du Hospital
Not yet recruiting
No outcome recorded
— NCT07491822 Mar 2026 → Sep 2027 expected triple-negative breast carcinoma Tianjin Medical University Cancer Institute and Hospital
Not yet recruiting
No outcome recorded
— NCT07092449 Aug 2025 → Dec 2027 expected gastroesophageal adenocarcinoma , gastroesophageal junction adenocarcinoma Tang-Du Hospital
Not yet recruiting
No outcome recorded
— NCT06966440 Jun 2025 → Jun 2028 expected pancreatic adenocarcinoma Ruijin Hospital
Recruiting
No outcome recorded
— NCT06853678 Feb 2025 → Jul 2026 overdue small cell lung carcinoma Tianjin Medical University Cancer Institute and Hospital
Recruiting
No outcome recorded
— NCT06341478 Mar 2024 → Mar 2026 overdue urinary bladder cancer IRCCS San Raffaele
Recruiting
No outcome recorded
— NCT05407155 Jun 2022 → Apr 2026 overdue non-small cell lung carcinoma Fudan University
Active not recruiting
No outcome recorded
— NCT04894643 Sep 2020 → Dec 2026 expected malignant pancreatic neoplasm EBG MedAustron GmbH
Recruiting
No outcome recorded
— NCT04017377 Sep 2019 → Jun 2020 cervical cancer Peking University Third Hospital
Unknown
No outcome recorded
— NCT02318095 Feb 2015 → Nov 2018 pancreatic exocrine neoplasm Duke University
Completed
No outcome recorded
— NCT01442974 Jan 2011 → Jan 2012 malignant pancreatic neoplasm Grupo Hospital de Madrid
Completed
No outcome recorded
— NCT00499291 Sep 2006 → ? cancer Eastern Cooperative Oncology Group
Withdrawn
No outcome recorded
Show 2 more trials Comparator or background therapy 408 trials
Phase 0
NCT03519308 Background Jul 2020 → Apr 2022 malignant pancreatic neoplasm Abramson Cancer Center at Penn Medicine
Terminated
No outcome recorded
Stop: Enrollment
Phase 0
NCT02550327 Background Jan 2016 → Jun 2021 pancreatic adenocarcinoma Baylor Research Institute
Completed
No outcome recorded
Phase 1
NCT07699757 Background Jul 2026 → Apr 2029 expected non-small cell lung carcinoma , pancreatic ductal adenocarcinoma Haisco Pharmaceutical Group Co., Ltd.
Not yet recruiting
No outcome recorded
Phase 1
NCT07348107 Background Feb 2026 → Mar 2027 expected pancreatic ductal adenocarcinoma Daniel Breadner
Not yet recruiting
No outcome recorded
Phase 1
NCT07024615 Background Oct 2025 → Jan 2028 expected pancreatic ductal adenocarcinoma Astellas Pharma Global Development, Inc.
Recruiting
No outcome recorded
Show all 408 trials opens the full record — a long page